Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP9 | Q86TI2 | 10/20 | 0.44 |
| ▸ | DPP4 | P27487 | 8/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2739683 | 1.00 | DPP9 (0.44) | DPP9DPP4DPP7PAX8DPP8 | |
| SCHEMBL10067240 | 1.00 | DPP9 (0.44) | DPP9DPP4DPP7PAX8DPP8 | |
| SCHEMBL1031741 | 0.84 | PAX8 (0.45) | DPP9DPP4DPP7PAX8DPP8 | |
| SCHEMBL8560140 | 0.84 | PAX8 (0.45) | DPP9DPP4DPP7PAX8DPP8 | |
| SCHEMBL16421636 | 0.82 | PAX8 (0.37) | DPP9DPP4DPP7PAX8DPP8 | |
| SCHEMBL25587465 | 0.82 | SLC7A5 (0.47) | PAX8CTSKSLC7A5 | |
| SCHEMBL14623137 | 0.81 | DPP9 (0.41) | DPP9DPP4DPP7PAX8DPP8 | |
| SCHEMBL24221417 | 0.79 | DPP9 (0.49) | DPP9DPP4DPP7DPP8SLC15A1 | |
| SCHEMBL1036161 | 0.79 | DPP4 (0.50) | DPP9DPP4DPP7PAX8DPP8 | |
| SCHEMBL14151828 | 0.79 | DPP4 (0.50) | DPP9DPP4DPP7PAX8DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863832-B1 | AGE INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2012-01-04 | — | — | EP | disclosed |
| WO-2006103274-A9 | AGE INHIBITORS | PHARMAMENS (FR) | 2007-01-18 | — | — | WO | disclosed |